The biotech has launched a strategic review to consider options, including a possible sale, following shareholder pressure.

Tempest Therapeutics is eyeing a strategic partner to continue amezalpat’s development amid ‘unavailable capital markets.’ ...

The UK's MHRA has been redesignated as one of the WHO’s collaborating centres for the standardisation and evaluation of ...

APHA executive director Dr Georges C Benjamin has called for HHS secretary Robert F Kennedy, Jr (RFK Jr) to "resign or be ...

On 7 April, at the 2025 American Academy of Neurology (AAN) meeting, a poster presentation by the Peking Union Medical ...

PharmaLogic is set to acquire a majority stake in Agilera Pharma to generate the CDMO focusing on radiopharmaceutical ...

The FDA has granted approval for the injectable antibiotic, Piperacillin and Tazobactam, to be used in B Braun's drug ...

The potential for cell and gene therapies is growing, offering groundbreaking treatments for rare genetic disorders and ...

US biotech Merida Biosciences has launched with $121m in Series A financing to develop therapeutics targeting disease-causing ...

The Inflation Reduction Act (IRA) is expected to influence the clinical development strategies of pharma companies profoundly ...

With liver ailments on the rise, and obesity a key driver, understanding the treatment options available is critical.

Degrees has signed a patent licence agreement with Yale School of Medicine for tafenoquine development for babesiosis.